Ozurdex®
(dexamethasone intravitreal implant) 0.7mg[1]

HELP BRIDGE THE REAL WORLD EFFICACY GAP[2-4]

Choose OZURDEX® for suitable naïve DME patients or those with insufficient response to anti-VEGF.[1] With an MOA shown to inhibit multiple inflammatory processes, OZURDEX® can help DME patients get real world visual acuity gains with a light injection schedule.[1-4]

IS IT TIME TO TREAD A DIFFERENT PATH?

OZURDEX® is indicated for the treatment of adult patients with macular edema due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), non-infectious uveitis affecting the posterior segment of the eye, diabetic macular edema. (DME) [1] **Real world evidence is collected outside of controlled clinical trials and has inherent limitations including a lesser ability to control for confounding factor. 1.** Ozurdex Product Insert April 2018. **2.** Boyer D *et al*. Ophthalmology 2014; 121(10):1904-14. **3.** odjikian A. et al. Hindawi Biomed Research International 2018, P 1-16. **4.** Pedro N. et al. Int J Ophthalmology Vol 14, No 10, 2021, P 1571-1580.

OZURDEX® (Dexamethasone 700 micrograms intravitreal implant in applicator) 1C 10/56 (N)

Abbreviated Prescribing Information: OZURDEX™ is an intravitreal implant containing 0.7 mg (700 µg) dexamethasone in the NOVADUR™ solid polymer drug delivery system. **PHARMACODYNAMICS:** Dexamethasone, a potent corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and phagocytic migration of inflammatory cells, inhibit the expression of VEGF. **PHARMACOKINETICS:** The majority of plasma dexamethasone concentrations were below the lower limit of quantitation (LLOQ= 50 pg/mL). **INDICATION:** Indicated for the treatment of adult patients with macular edema due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), non-infectious uveitis affecting the posterior segment of the eye, diabetic macular edema. **RECOMMEND DOSE:** For ophthalmic intravitreal injection only. The recommended dose is 0.7 mg per eye. Reinjection of OZURDEX™ 0.7 mg is recommended when there is a reoccurrence of macular edema or vascular leakage in the macula. **CONTRAINDICATION:** Ocular or Periocular Infections. Advanced Glaucoma. Aphakic eyes with ruptured posterior lens capsule. Anterior chamber intraocular lens, iris or transscleral fixated IOLs and ruptured posterior lens capsule. Known hypersensitivity to dexamethasone or to any components of this product. **WARNINGS AND PRECAUTIONS:** Intravitreal injections have been associated with endophthalmitis, intraocular inflammation, increased intraocular pressure, and retinal detachment. Risk of Implant Migration. *Potential Steroid-related Effects:* Increased intraocular pressure, glaucoma, may enhance the establishment of secondary ocular infections Corticosteroids should be used cautiously in patients with a history of ocular herpes simplex and not be used in active ocular herpes simplex. Patients may experience temporary visual blurring after receiving an intravitreal injection. **STORAGE:** Store below 30°C (86°F) *Manufactured by:* Allergan Pharmaceuticals Ireland Castlebar Road, Westport, Co. Mayo, Ireland. *Imported by:* Allergan (Thailand) Limited, Bangkok.

โปรดอ่านรายละเอียดเพิ่มเติมในเอกสารอ้างอิงฉบับสมบูรณ์และเอกสารกำกับยา
ใบอนุญาตโฆษณาเลขที่ ข.ศ. 89/2565

Allergan an AbbVie company
Allergan (Thailand) Limited
973 President Tower, 8th and 11th Floors, Room Nos. 8E and 11K, Ploenchit Road, Lumpini, Pathumwan, Bangkok 10330

TH-OZU-220024 23 Feb 2022